

INHIBITOR NIJMEGEN BETHESDA ASSAYS

FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS

INHIBITOR CONTROLS

Lyophilized plasmas



Factor VIII Inhibitor Plasma



Associated products

CRYOcheck™ Factor VIII Inhibitor Kit
Factor IX Inhibitor Plasma Negative Control
Factor IX Inhibitor Plasma Weak Control
Factor VIII Inhibitor Plasma HCV neg
Factor VIII Inhibitor Plasma Negative Control
Factor VIII Inhibitor Plasma Weak Control

Informations

Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.

The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control. The activity of the inhibitor is measured by the Bethesda assays or modified Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FVIII for hemophilia A.


Reference	Presentation	Format
4-5159008	Vial	5 x 1.0 mL

Human hemophilia A plasma containing a natural anti-FVIII inhibitor.
This plasma can be used for the control of the determination of Factor VIII (FVIII) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.

Factor VIII Inhibitor control plasma is human hemophilia A plasma containing a specific natural antibody directed against FVIII (FVIII: C) activity.

Components

- 5 vials x 1 mL lyophilized plasma



Characteristics

Plasma with Factor VIII inhibitor can be used :

- As a plasma sample from a patient with hemophilia A with a Factor VIII inhibitor
- For accuracy control of Factor VIII inhibitor determination based on the Bethesda Test
- Title in Bethesda Unit depending on lots and tests
- 1 month stability after reconstitution

